Duration of preclinical, prodromal, and dementia stages of Alzheimer's disease in relation to age, sex, and APOE genotype

Lisa Vermunt*, Sietske A. M. Sikkes, Ardo van den Hout, Ron Handels, Isabelle Bos, Wiesje M. van der Flier, Silke Kern, Pierre-Jean Ousset, Paul Maruff, Ingmar Skoog, Frans R. J. Verhey, Yvonne Freund-Levi, Magda Tsolaki, Asa K. Wallin, Marcel Olde Rikkert, Hilkka Soininen, Luisa Spiru, Henrik Zetterberg, Kaj Blennow, Philip ScheltensGraciela Muniz-Terrera, Pieter Jelle Visser, B. Vellas, E. Reynish, P. J. Ousset, S. Andrieu, A. Burns, F. Pasquier, G. Frisoni, E. Salmon, J. P. Michel, D. S. Zekry, M. Boada, J. F. Dartigues, M. G. M. Olde-Rikkert, A. S. Rigaud, B. Winblad, A. Malick, A. Sinclair, L. Froelich, P. Scheltens, C. Ribera, J. Touchon, P. Robert, A. Salva, G. Waldemar, R. Bullock, M. Tsolaki, G. Rodriguez, L. Spiru, Alzheimer's Disease Neuroimaging Initiative, AIBL Research Group, ICTUS study group, DSA Study Group

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

16 Downloads (Pure)
Original languageEnglish
Pages (from-to)888-898
Number of pages11
JournalAlzheimer's & Dementia
Volume15
Issue number7
DOIs
Publication statusPublished - Jul 2019

Keywords

  • Alzheimer's disease
  • Disease duration
  • Preclinical
  • Prodromal
  • Dementia
  • APOE
  • Clinical setting
  • Progression
  • Multistate model
  • MILD COGNITIVE IMPAIRMENT
  • BETA-AMYLOID 1-42
  • ASSOCIATION WORKGROUPS
  • DIAGNOSTIC GUIDELINES
  • NATIONAL INSTITUTE
  • RISK-FACTORS
  • DECLINE
  • PREVALENCE
  • NEURODEGENERATION
  • RECOMMENDATIONS

Cite this